{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:38:00Z","timestamp":1785497880860,"version":"3.56.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pan-American Infectious Diseases Association"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Since the beginning of the COVID-19 pandemic, therapeutic options for treating COVID-19 have been investigated at different stages of clinical manifestations. Considering the particular impact of COVID-19 in the Americas, this document aims to present recommendations for the pharmacological treatment of COVID-19 specific to this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fifteen experts, members of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API) make up the panel responsible for developing this guideline. Questions were formulated regarding prophylaxis and treatment of COVID-19 in outpatient and inpatient settings. The outcomes considered in decision-making were mortality, hospitalisation, need for mechanical ventilation, symptomatic COVID-19 episodes, and adverse events. In addition, a systematic review of randomised controlled trials was conducted. The quality of evidence assessment and guideline development process followed the GRADE system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine technologies were evaluated, and ten recommendations were made, including the use of tixagevimab\u2009+\u2009cilgavimab in the prophylaxis of COVID-19, tixagevimab\u2009+\u2009cilgavimab, molnupiravir, nirmatrelvir\u2009+\u2009ritonavir, and remdesivir in the treatment of outpatients, and remdesivir, baricitinib, and tocilizumab in the treatment of hospitalised patients with severe COVID-19. The use of hydroxychloroquine or chloroquine and ivermectin was discouraged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This guideline provides recommendations for treating patients in the Americas following the principles of evidence-based medicine. The recommendations present a set of drugs that have proven effective in the prophylaxis and treatment of COVID-19, emphasising the strong recommendation for the use of nirmatrelvir\/ritonavir in outpatients as the lack of benefit from the use of hydroxychloroquine and ivermectin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12941-023-00623-w","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T13:02:06Z","timestamp":1691413326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pan-American Guidelines for the treatment of SARS-CoV-2\/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API)"],"prefix":"10.1186","volume":"22","author":[{"given":"Alexandre Naime","family":"Barbosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Chebabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clevy","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00f3vis Arns","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"de Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estev\u00e3o Portela","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Carvalho","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Croda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maicon","family":"Falavigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica Maria","family":"Gomes-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Thormann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Cimerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suena Medeiros","family":"Parahiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana","family":"Tanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanderley Marques","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso J.","family":"Rodriguez-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"623_CR1","unstructured":"Therapeutics and COVID-19: Living guideline. 2023. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2022.5. Accessed 31 Jan 2023."},{"issue":"2","key":"623_CR2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jhin.2020.04.002","volume":"105","author":"JA Al-Tawfiq","year":"2020","unstructured":"Al-Tawfiq JA, Rodriguez-Morales AJ. Super-spreading events and contribution to transmission of MERS, SARS, and SARS-CoV-2 (COVID-19). J Hosp Infect. 2020;105(2):111\u20132.","journal-title":"J Hosp Infect"},{"key":"623_CR3","unstructured":"COVID-19 Dashboard. https:\/\/coronavirus.jhu.edu\/map.html. Accessed 31 Jan 2023."},{"key":"623_CR4","unstructured":"WHO Coronavirus (COVID-19) Dashboard https:\/\/covid19.who.int\/table. Accessed 31 Jan 2023."},{"issue":"12","key":"623_CR5","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1080\/21645515.2020.1788310","volume":"16","author":"M Iqbal Yatoo","year":"2020","unstructured":"Iqbal Yatoo M, Hamid Z, Parray OR, Wani AH, Ul Haq A, Saxena A, Patel SK, Pathak M, Tiwari R, Malik YS, et al. COVID-19\u2014recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines. Hum Vaccin Immunother. 2020;16(12):2891\u2013904.","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"623_CR6","doi-asserted-by":"crossref","first-page":"e1004107","DOI":"10.1371\/journal.pmed.1004107","volume":"19","author":"I Bergeri","year":"2022","unstructured":"Bergeri I, Whelan MG, Ware H, Subissi L, Nardone A, Lewis HC, Li Z, Ma X, Valenciano M, Cheng B, et al. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: a systematic review and meta-analysis of standardized population-based studies. PLoS Med. 2022;19(11):e1004107.","journal-title":"PLoS Med"},{"issue":"1","key":"623_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2023.2143347","volume":"22","author":"R Solante","year":"2023","unstructured":"Solante R, Alvarez-Moreno C, Burhan E, Chariyalertsak S, Chiu NC, Chuenkitmongkol S, Dung DV, Hwang KP, Ortiz Ibarra J, Kiertiburanakul S, et al. Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. Expert Rev Vaccines. 2023;22(1):1\u201316.","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"623_CR8","doi-asserted-by":"crossref","first-page":"146","DOI":"10.15585\/mmwr.mm7104e4","volume":"71","author":"AD Iuliano","year":"2022","unstructured":"Iuliano AD, Brunkard JM, Boehmer TK, Peterson E, Adjei S, Binder AM, Cobb S, Graff P, Hidalgo P, Panaggio MJ, et al. Trends in disease severity and health care utilization during the early omicron variant period compared with previous SARS-CoV-2 high transmission periods\u2014United States, December 2020\u2013January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):146\u201352.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"623_CR9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","volume":"66","author":"J Andrews","year":"2013","unstructured":"Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, Nasser M, Meerpohl J, Post PN, Kunz R, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719\u201325.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"623_CR10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401\u20136.","journal-title":"J Clin Epidemiol"},{"key":"623_CR11","unstructured":"Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html. Accessed 1 Aug 2023."},{"issue":"23","key":"623_CR12","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, et al. Intramuscular AZD7442 (Tixagevimab\u2013Cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386(23):2188\u2013200.","journal-title":"N Engl J Med"},{"issue":"10","key":"623_CR13","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","volume":"10","author":"H Montgomery","year":"2022","unstructured":"Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seegobin S, Kim K, Campos JAS, Arends RH, Brodek BH, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022;10(10):985\u201396.","journal-title":"Lancet Respir Med"},{"key":"623_CR14","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4042673","author":"SKL Tippabhotla","year":"2022","unstructured":"Tippabhotla SKL, Lahiri S, Raju DR, Kandi C, Naga PV. Efficacy and safety of molnupiravir for the treatment of non-hospitalized adults with mild COVID-19: a randomized, open-label, parallel-group phase 3 trial. SSRN. 2022. https:\/\/doi.org\/10.2139\/ssrn.4042673.","journal-title":"SSRN"},{"issue":"6","key":"623_CR15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2022","unstructured":"Jayk Bernal A, Da Silva MMG, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Mart\u00edn-Quir\u00f3s A, Caraco Y, Williams-Diaz A, Brown ML, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509\u201320.","journal-title":"N Engl J Med"},{"issue":"15","key":"623_CR16","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Sim\u00f3n-Campos A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397\u2013408.","journal-title":"N Engl J Med"},{"issue":"4","key":"623_CR17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","volume":"386","author":"RL Gottlieb","year":"2022","unstructured":"Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386(4):305\u201315.","journal-title":"N Engl J Med"},{"key":"623_CR18","first-page":"100243","volume":"11","author":"\u00c1 Avezum","year":"2022","unstructured":"Avezum \u00c1, Oliveira GBF, Oliveira H, Lucchetta RC, Pereira VFA, Dabarian AL, Ricardo D, Vieira O, Silva DV, Kormann APM, Tognon AP, et al. Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE\u2014Coalition V): a double-blind, multicentre, randomised, controlled trial. Lancet Reg Health Am. 2022;11:100243.","journal-title":"Lancet Reg Health Am"},{"issue":"11","key":"623_CR19","doi-asserted-by":"crossref","first-page":"e4073","DOI":"10.1093\/cid\/ciaa1009","volume":"73","author":"O Mitj\u00e0","year":"2021","unstructured":"Mitj\u00e0 O, Corbacho-Monn\u00e9 M, Ubals M, Teb\u00e9 C, Pe\u00f1afiel J, Tobias A, Ballana E, Alemany A, Riera-Mart\u00ed N, P\u00e9rez CA, et al. Hydroxychloroquine for early treatment of adults with mild coronavirus disease 2019: a randomized, controlled trial. Clin Infect Dis. 2021;73(11):e4073\u201381.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"623_CR20","doi-asserted-by":"crossref","first-page":"e216468","DOI":"10.1001\/jamanetworkopen.2021.6468","volume":"4","author":"G Reis","year":"2021","unstructured":"Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Singh G, Park JJH, Forrest JI, Harari O, Dos Santos CVQ, De Almeida APFG, et al. Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19. JAMA Netw Open. 2021;4(4):e216468.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"623_CR21","doi-asserted-by":"crossref","first-page":"E693","DOI":"10.9778\/cmajo.20210069","volume":"9","author":"I Schwartz","year":"2021","unstructured":"Schwartz I, Boesen ME, Cerchiaro G, Doram C, Edwards BD, Ganesh A, Greenfield J, Jamieson S, Karnik V, Kenney C, et al. Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. CMAJ Open. 2021;9(2):E693\u2013702.","journal-title":"CMAJ Open"},{"issue":"8","key":"623_CR22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.7326\/M20-4207","volume":"173","author":"CP Skipper","year":"2020","unstructured":"Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, Williams DA, Okafor EC, Pullen MF, Nicol MR, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Intern Med. 2020;173(8):623\u201331.","journal-title":"Ann Intern Med"},{"key":"623_CR23","doi-asserted-by":"crossref","first-page":"100645","DOI":"10.1016\/j.eclinm.2020.100645","volume":"29","author":"AS Omrani","year":"2020","unstructured":"Omrani AS, Pathan SA, Thomas SA, Harris TRE, Coyle PV, Thomas CE, Qureshi I, Bhutta ZA, Mawlawi NA, Kahlout RA, et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine. 2020;29:100645.","journal-title":"EClinicalMedicine"},{"issue":"14","key":"623_CR24","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jama.2021.3071","volume":"325","author":"E L\u00f3pez-Medina","year":"2021","unstructured":"L\u00f3pez-Medina E, L\u00f3pez P, Hurtado IC, D\u00e1valos DM, Ramirez O, Mart\u00ednez E, D\u00edazgranados JA, O\u00f1ate JM, Chavarriaga H, Herrera S, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19. JAMA. 2021;325(14):1426.","journal-title":"JAMA"},{"issue":"16","key":"623_CR25","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/jama.2022.18590","volume":"328","author":"S Naggie","year":"2022","unstructured":"Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Gentile N, Collins S, McCarthy MW, Jayaweera D, Castro M, Sulkowski M, et al. Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19. JAMA. 2022;328(16):1595.","journal-title":"JAMA"},{"issue":"18","key":"623_CR26","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1056\/NEJMoa2115869","volume":"386","author":"G Reis","year":"2022","unstructured":"Reis G, Silva EASM, Silva DCM, Thabane L, Milagres AC, Ferreira TS, Dos Santos CVQ, Campos VHS, Nogueira AMR, De Almeida APFG, et al. Effect of early treatment with ivermectin among patients with Covid-19. N Engl J Med. 2022;386(18):1721\u201331.","journal-title":"N Engl J Med"},{"issue":"10339","key":"623_CR27","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","volume":"399","author":"WHO Solidarity Trial Consortium","year":"2022","unstructured":"WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO solidarity randomised trial and updated meta-analyses. Lancet. 2022;399(10339):1941\u201353.","journal-title":"Lancet"},{"issue":"3","key":"623_CR28","doi-asserted-by":"publisher","first-page":"886","DOI":"10.4269\/ajtmh.21-0606","volume":"106","author":"S Abd-Elsalam","year":"2021","unstructured":"Abd-Elsalam S, Ahmed OA, Mansour NO, Abdelaziz DH, Salama M, Fouad MHA, Soliman S, Naguib AM, Hantera MS, Ibrahim IS, et al. Remdesivir efficacy in COVID-19 treatment: a randomized controlled trial. Am J Trop Med Hyg. 2021. https:\/\/doi.org\/10.4269\/ajtmh.21-0606.","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"623_CR29","doi-asserted-by":"crossref","first-page":"E242","DOI":"10.1503\/cmaj.211698","volume":"194","author":"K Ali","year":"2022","unstructured":"Ali K, Azher T, Baqi M, Binnie A, Borgia S, Carrier FM, Cavayas YA, Chagnon N, Cheng MP, Conly J, et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. Can Med Assoc J. 2022;194(7):E242\u201351.","journal-title":"Can Med Assoc J"},{"issue":"19","key":"623_CR30","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, et al. Remdesivir for the treatment of Covid-19\u2014final report. N Engl J Med. 2020;383(19):1813\u201326.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"623_CR31","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.4103\/ija.IJA_149_21","volume":"65","author":"L Mahajan","year":"2021","unstructured":"Mahajan L, Singh AP. Gifty: clinical outcomes of using remdesivir in patients with moderate to severe COVID-19\u2014a prospective randomised study. Indian J Anaesth. 2021. https:\/\/doi.org\/10.4103\/ija.IJA_149_21.","journal-title":"Indian J Anaesth"},{"issue":"11","key":"623_CR32","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","volume":"324","author":"CD Spinner","year":"2020","unstructured":"Spinner CD, Gottlieb RL, Criner GJ, Arribas L\u00f3pez JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. JAMA. 2020;324(11):1048.","journal-title":"JAMA"},{"issue":"10236","key":"623_CR33","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020;395(10236):1569\u201378.","journal-title":"The Lancet"},{"issue":"2","key":"623_CR34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","volume":"22","author":"F Ader","year":"2022","unstructured":"Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, L\u00ea M-P, Peytavin G, Staub T, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022;22(2):209\u201321.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"623_CR35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","volume":"10","author":"EW Ely","year":"2022","unstructured":"Ely EW, Ramanan AV, Kartman CE, De Bono S, Liao R, Piruzeli MLB, Goldman JD, Saraiva JFK, Chakladar S, Marconi VC, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10(4):327\u201336.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"623_CR36","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","volume":"9","author":"VC Marconi","year":"2021","unstructured":"Marconi VC, Ramanan AV, De Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, De Cassia PR, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407\u201318.","journal-title":"Lancet Respir Med"},{"issue":"10285","key":"623_CR37","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637\u201345.","journal-title":"Lancet"},{"issue":"6","key":"623_CR38","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.cmi.2022.02.027","volume":"28","author":"N Broman","year":"2022","unstructured":"Broman N, Feuth T, Vuorinen T, Valtonen M, Hohenthal U, L\u00f6yttyniemi E, Hirvioja T, Jalava-Karvinen P, Marttila H, Nordberg M, et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clin Microbiol Infect. 2022;28(6):844\u201351.","journal-title":"Clin Microbiol Infect"},{"key":"623_CR39","doi-asserted-by":"crossref","first-page":"101362","DOI":"10.1016\/j.eclinm.2022.101362","volume":"46","author":"O Hermine","year":"2022","unstructured":"Hermine O, Mariette X, Porcher R, Djossou F, Nguyen Y, Arlet JB, Savale L, Diehl JL, Georgin-Lavialle S, Cadranel J, et al. Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: a randomised clinical trial from the CORIMUNO-19 study group. EClinicalMedicine. 2022;46:101362.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"623_CR40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","volume":"181","author":"O Hermine","year":"2021","unstructured":"Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P, CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized With COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):32\u201340.","journal-title":"JAMA Intern Med"},{"issue":"16","key":"623_CR41","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","volume":"384","author":"IO Rosas","year":"2021","unstructured":"Rosas IO, Br\u00e4u N, Waters M, Go R, Hunter BD, Bhagani S, Skiest D, Aziz MS, Cooper N, Douglas IS, et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia.\u00a0 N Engl J Med\n. 2021;384(16):1503\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2028700.","journal-title":"N Engl J Med"},{"issue":"1","key":"623_CR42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","volume":"384","author":"C Salama","year":"2020","unstructured":"Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, Criner GJ, Kaplan-Lewis E, Baden R, Pandit L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2020;384(1):20\u201330.","journal-title":"N Engl J Med"},{"issue":"1","key":"623_CR43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","volume":"181","author":"C Salvarani","year":"2021","unstructured":"Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, Bruzzi P, Boni F, Braglia L, Turr\u00e0 C, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):24\u201331.","journal-title":"JAMA Intern Med"},{"issue":"24","key":"623_CR44","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","volume":"383","author":"JH Stone","year":"2020","unstructured":"Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333\u201344.","journal-title":"N Engl J Med"},{"key":"623_CR45","doi-asserted-by":"crossref","first-page":"n84","DOI":"10.1136\/bmj.n84","volume":"372","author":"VC Veiga","year":"2021","unstructured":"Veiga VC, Prats JAGG, Farias DLC, Rosa RG, Dourado LK, Zampieri FG, Machado FR, Lopes RD, Berwanger O, Azevedo LCP, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021;372:n84.","journal-title":"BMJ"},{"issue":"12","key":"623_CR46","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S2213-2600(21)00377-5","volume":"9","author":"J Declercq","year":"2021","unstructured":"Declercq J, Van Damme KFA, De Leeuw E, Maes B, Bosteels C, Tavernier SJ, De Buyser S, Colman R, Hites M, Verschelden G, et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respir Med. 2021;9(12):1427\u201338.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"623_CR47","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(21)00081-3","volume":"9","author":"AS Soin","year":"2021","unstructured":"Soin AS, Kumar K, Choudhary NS, Sharma P, Mehta Y, Kataria S, Govil D, Deswal V, Chaudhry D, Singh PK, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021;9(5):511\u201321.","journal-title":"Lancet Respir Med"},{"key":"623_CR48","volume-title":"Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 the REMAP-CAP COVID-19 immune modulation therapy domain randomized clinical trial","author":"LPG Derde","year":"2021","unstructured":"Derde LPG. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 the REMAP-CAP COVID-19 immune modulation therapy domain randomized clinical trial. Cold Spring Harbor: Cold Spring Harbor Laboratory; 2021."},{"issue":"1","key":"623_CR49","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1038\/s41598-022-08882-x","volume":"12","author":"AM Camon","year":"2022","unstructured":"Camon AM, Alonso R, Mu\u00f1oz FJ, Cardozo C, Bernal-Maurandi J, Albiach L, Ag\u00fcero D, Marcos MA, Ambrosioni J, Bodro M, et al. C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19. Sci Rep. 2022;12(1):5250.","journal-title":"Sci Rep"},{"issue":"3","key":"623_CR50","doi-asserted-by":"crossref","first-page":"100549","DOI":"10.1016\/j.xcrm.2022.100549","volume":"3","author":"M Singh","year":"2022","unstructured":"Singh M, De Wit E. Antiviral agents for the treatment of COVID-19: progress and challenges. Cell Rep Med. 2022;3(3):100549.","journal-title":"Cell Rep Med"},{"issue":"4","key":"623_CR51","first-page":"00236","volume":"8","author":"DA Wohl","year":"2022","unstructured":"Wohl DA, Espinueva AA, Dau L, Wang C-Y, Lachmann A, Bam RA, Rawal A, Chappell-Smith K, Rockstroh JK. COVID-19 therapies for inpatients: a review and quality assessment of clinical guidelines. ERJ Open Res. 2022;8(4):00236\u20132022.","journal-title":"ERJ Open Res"},{"issue":"2","key":"623_CR52","doi-asserted-by":"crossref","first-page":"102347","DOI":"10.1016\/j.bjid.2022.102347","volume":"26","author":"M Falavigna","year":"2022","unstructured":"Falavigna M, Belli KC, Barbosa AN, Zavascki AP, Nastri ACDSS, Santana CM, Stein C, Gr\u00e4f DD, Cadegiani FA, Guimar\u00e3es HP, et al. Brazilian guidelines for the treatment of outpatients with suspected or confirmed COVID-19. A joint guideline of the Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Medical Association (AMB), Brazilian Society of Angiology and Vascular S. Br J Infect Dis. 2022;26(2):102347.","journal-title":"Br J Infect Dis"},{"issue":"1","key":"623_CR53","first-page":"1","volume":"34","author":"M Falavigna","year":"2022","unstructured":"Falavigna M, Stein C, Amaral JLGD, Azevedo LCPD, Belli KC, Colpani V, Cunha CAD, Dal-Pizzol F, Dias MBS, Ferreira JC, et al. Diretrizes Brasileiras para o tratamento farmacol\u00f3gico de pacientes hospitalizados com COVID-19. Revista Brasileira de Terapia Intensiva. 2022;34(1):1\u201312.","journal-title":"Revista Brasileira de Terapia Intensiva"},{"key":"623_CR54","doi-asserted-by":"crossref","unstructured":"Bhimraj A MR, Shumaker AH, Baden L, Cheng VC, Edwards KM, Gallagher JC, Gandhi RT, Muller WJ, Nakamura MM, O'Horo JC, Shafer RW, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Version 10.1.1. Infectious Diseases Society of America. 2022.","DOI":"10.1093\/cid\/ciac724"},{"issue":"4","key":"623_CR55","first-page":"480","volume":"30","author":"RA Farahat","year":"2022","unstructured":"Farahat RA, Abdelaal A, Umar TP, El-Sakka AA, Benmelouka AY, Albakri K, Ali I, Al-Ahdal T, Abdelazeem B, Sah R, et al. The emergence of SARS-CoV-2 Omicron subvariants: current situation and future trends. Infez Med. 2022;30(4):480\u201394.","journal-title":"Infez Med"},{"key":"623_CR56","unstructured":"Atualiza\u00e7\u00e3o sobre a emerg\u00eancia de sublinhagens de \u00d4micron de SARS- CoV-2 eventos de recombina\u00e7\u00e3o. https:\/\/www.paho.org\/pt\/documentos\/atualizacao-sobre-emergencia-sublinhagens-omicron-sars-cov-2-eventos-recombinacao. Accessed 31 Jan 2023."},{"key":"623_CR57","volume-title":"TAG-VE statement on omicron sublineages BQ.1 and XBB","author":"WH Organization","year":"2022","unstructured":"WH Organization. TAG-VE statement on omicron sublineages BQ.1 and XBB. Geneva: WHO; 2022."},{"key":"623_CR58","doi-asserted-by":"crossref","first-page":"102234","DOI":"10.1016\/j.tmaid.2021.102234","volume":"45","author":"S Poudel","year":"2022","unstructured":"Poudel S, Ishak A, Perez-Fernandez J, Garcia E, Le\u00f3n-Figueroa DA, Roman\u00ed L, Bonilla-Aldana DK, Rodriguez-Morales AJ. Highly mutated SARS-CoV-2 omicron variant sparks significant concern among global experts\u2014what is known so far? Travel Med Infect Dis. 2022;45:102234.","journal-title":"Travel Med Infect Dis"},{"issue":"1","key":"623_CR59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/jcm11010030","volume":"11","author":"H Nishiura","year":"2021","unstructured":"Nishiura H, Ito K, Anzai A, Kobayashi T, Piantham C, Rodr\u00edguez-Morales AJ. Relative reproduction number of SARS-CoV-2 omicron (B.1.1.529) compared with delta variant in South Africa. J Clin Med. 2021;11(1):30.","journal-title":"J Clin Med"},{"key":"623_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00733-2","author":"P Arora","year":"2022","unstructured":"Arora P, Kempf A, Nehlmeier I, Schulz SR, J\u00e4ck H-M, P\u00f6hlmann S, Hoffmann M. Omicron sublineage BQ.1.1 resistance to monoclonal antibodies. Lancet Infect Dis. 2022. https:\/\/doi.org\/10.1016\/S1473-3099(22)00733-2.","journal-title":"Lancet Infect Dis"},{"key":"623_CR61","unstructured":"COVID data tracker\u2014variant proportions https:\/\/covid.cdc.gov\/covid-data-tracker\/#variant-proportions Accessed 31 Jan 2023."},{"key":"623_CR62","unstructured":"FDA announces Evusheld is not currently authorized for emergency use in the U.S. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-evusheld-not-currently-authorized-emergency-use-us Accessed 31 Jan 2023."},{"key":"623_CR63","first-page":"692","volume":"380","author":"F Lamontagne","year":"2023","unstructured":"Lamontagne F, Stegemann M, Agarwal A, Agoritsas T, Siemieniuk R, Rochwerg B, Bartoszko J, Askie L, Macdonald H, Al-Maslamani M, Amin W. Update to living WHO guideline on drugs to prevent covid-19. BMJ. 2023;380:692.","journal-title":"BMJ"},{"key":"623_CR64","doi-asserted-by":"crossref","first-page":"m2980","DOI":"10.1136\/bmj.m2980","volume":"370","author":"RA Siemieniuk","year":"2020","unstructured":"Siemieniuk RA, Bartoszko JJ, Zeraatkar D, Kum E, Qasim A, Martinez JPD, Izcovich A, Lamontagne F, Han MA, Agarwal A, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980.","journal-title":"BMJ"},{"key":"623_CR65","doi-asserted-by":"crossref","first-page":"102606","DOI":"10.1016\/j.tmaid.2023.102606","volume":"54","author":"AJ Rodriguez-Morales","year":"2023","unstructured":"Rodriguez-Morales AJ, Lopez-Echeverri MC, Perez-Raga MF, Quintero-Romero V, Valencia-Gallego V, Galindo-Herrera N, L\u00f3pez-Alzate S, S\u00e1nchez-Vinasco JD, Guti\u00e9rrez-Vargas JJ, Mayta-Tristan P, et al. The global challenges of the long COVID-19 in adults and children. Travel Med Infect Dis. 2023;54:102606.","journal-title":"Travel Med Infect Dis"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-023-00623-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-023-00623-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-023-00623-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T14:17:19Z","timestamp":1700230639000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-023-00623-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["623"],"URL":"https:\/\/doi.org\/10.1186\/s12941-023-00623-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2603347\/v1","asserted-by":"object"}]},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"assertion":[{"value":"19 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MF received consulting fees related to COVID-19 from Pfizer and MSD outside the context of the present study.\u00a0AJRM received support from API to participate at on-site meetings in Brazil, also from Gilead Brazil for the 2023 meeting. CP, DL, GZ, JCF, MT, SMP, ST, and WMB have no direct financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}